Status:

COMPLETED

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

Lead Sponsor:

Laboratorios Sophia S.A de C.V.

Conditions:

Safety

Tolerability

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

Clinical phase I, controlled, non comparative, open, single center study evaluating the safety and tolerability of ophthalmic solution PRO-172 when applied on the ocular surface of healthy volunteers.

Eligibility Criteria

Inclusion

  • Clinically healthy volunteers
  • Being capable of voluntarily grant a signed informed consent.
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Being between 18 and 45 years old.
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method of intrauterine device (IUD) during the study.
  • Having a best corrected visual acuity equal or better than 20/30 in both eyes.
  • Showing normal vital signs.
  • Having an intraocular pressure between 10 and 21 mmHg.

Exclusion

  • Using any kind of ophthalmic topical product.
  • Using drugs or herbal products, through any administration route.
  • For women: pregnancy, breastfeeding or planning to become pregnant during the time of the study.
  • Having participated in clinical trials 90 days prior to inclusion in this study.
  • Having participated previously in this study.
  • Using contact lenses and not being able to suspend such use during the period of the study.
  • Being unable to follow the lifestyle modification considerations required for the study.
  • Having started the use of hormonal contraceptives of IUD within 30 days previous of inclusion in this study.
  • Suffering any chronic degenerative diseases.
  • Suffering active inflammatory of infectious disease when entering this study.
  • Suffering unresolved lesions or traumas when entering this study.
  • Having a previous history of any kind of ocular surgery.
  • Having a previous history of any surgical procedure, non ophthalmological, within the last 3 months.

Key Trial Info

Start Date :

September 24 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 8 2020

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT04693429

Start Date

September 24 2020

End Date

December 8 2020

Last Update

July 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Unidad Clínica de Bioequivalencia, S. de R.L. de C.V.

Guadalajara, Jalisco, Mexico, 44190

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ | DecenTrialz